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INTRODUCTION
The avoidance of CYP2D6-mediated drug metabolism represents an early project management criteria in drug development due to its potential for variable patient safety and drug efficacy arising from genetic polymorphisms and its involvement in the metabolism of many existing drugs (Kramer et al., 2007; Leeson and Springthorpe, 2007) . An example of an unwanted, variable patient response due to CYP2D6 polymorphisms is the response to codeine, which requires CYP2D6 conversion to the active drug morphine. Patients with a "slow metabolizer" phenotype due to altered CYP2D6 expression or function can experience reduced analgesic effects resulting from diminished morphine production. In contrast, mutations causing a "rapid metabolizer" phenotype increase toxicity risks as excessive levels of morphine can be produced (Kirchheiner et al., 2007) . As a result of such variance, there is considerable interest in identifying features that make small molecules favorable CYP2D6 substrates to prioritize early discovery efforts towards compounds with a lower likelihood of CYP2D6 involvement.
The prevailing model of favorable CYP2D6 substrates includes the presence of a basic, protonated nitrogen atom 5, 7 or 10 Å from the site of metabolism (de Groot et al., 1997 ), but the model cannot accommodate substrates lacking the protonated nitrogen or nonsubstrates that possess the protonated nitrogen (Guengerich et al., 2002) . Characterization of what makes a particular small molecule a CYP2D6 substrate is often done through examination of how structural changes alter discrete properties and CYP2D6 substrate status (Kalgutkar et al., 2003; Upthagrove et al., 2001) . Such investigations provide insight into the features influencing CYP2D6 substrate status for specific sets of small molecules, but the trends cannot necessarily be generalized across other small molecule drug candidates. In the absence of general models that can be applied with confidence to any small molecule drug discovery campaign, ongoing projects must synthesize and experimentally screen all possible candidates for potential CYP2D6 substrate status.
The importance of first pass metabolism of drugs by CYP2D6 is of greater impact for CNS drugs (Goodwin and Clark, 2005) , where inspection of the DrugBank database (Wishart et al., 2008) However, CNS drugs constitute only a small percentage (≤5%) of approved therapeutics (Wishart et al., 2008) , making the detection of statistically significant trends difficult. As an alternative, analysis of structurally related small molecule CNS drugs has the potential to test prevailing hypotheses and provide insight. In this regard, minaprine and minozac provide a novel study of structurally similar compounds (Tanimoto similarity coefficient = 0.71) with distinct pharmacology and CNS activity that also differ in their CYP2D6 substrate status. In terms of prevailing models, the difference in CYP2D6 status of minaprine and minozac cannot be explained by differences in lipophilicity (de Groot et al., 1997) since the compounds possess nearly identical experimental LogP values of 1.9 (Arnaud-Neu et al., 1990 ) and 2.3 (Hu et al., 2007) , respectively. Although minaprine adheres to the prevailing localized charge model for CYP2D6 substrate status (de Groot et al., 1997) , in that it is more basic than the nonsubstrate minozac, and a quantitative model of CYP2D6 substrates provides an accurate forecast for minaprine (Haji-Momenian et al., 2003) , the QSAR model cannot explain why minozac is not a substrate.
In order to gain insight into the molecular basis of the CYP2D6 substrate differences for minaprine and minozac, we sought to interconvert minaprine from a substrate to a non-substrate, and minozac from a non-substrate to a substrate. This was done by synthesis of analogs for each CNS drug and evaluating the CYP2D6 enzyme kinetics for each compound. The trend in molecular properties when a substrate is transformed into a non-substrate, and vice versa, does not follow a simple correlation with any given single molecular property, but suggests an indirect effect of charge and molecular volume. As part of an effort to place these results into a larger context, we generated a parsed database of CYP2D6 substrates from the available literature and subjected it to database mining analysis. The analyses identified complex relationships between CYP2D6 K M values and molecular properties related to charge, lipophilicity and molecule size, with the pattern of properties depending upon the particular chemical scaffold being examined, consistent with the outcomes from the comparative evaluation of minaprine and minozac.
This article has not been copyedited and formatted. The final version may differ from this version. Analytical Chemistry. All HPLC analytical data were obtained on a commercially available system from Dionex Corp. (Sunnyvale, CA) using a Phenomenex (Torrance, CA) Luna C18 column (250 x 2.0mm; 5micron) with guard column as previously described (Hu et al., 2007) . Peak quantification was done based upon absorption measurements at 260nm relative to a standard curve obtained by serial dilutions of compounds. The mobile phase consisted of 0.1% (v/v) formic acid in water as reagent A and acetonitrile with 0.1% (v/v) formic acid in water as reagent B at a flow rate of 0.2ml/min. Final compounds were characterized by electrospray mass spectroscopy (ESI), HPLC and 1 H NMR. All intermediates were characterized minimally by ESI and HPLC. NMR spectra were acquired on a Varian Inova 500 MHz spectrometer at room temperature. ESI mass spectra were collected on a Micromass Quattro II Triple Quadrupole HPLC/MS/MS mass spectrometer.
Determination of Michaelis Constants (K M ) by Substrate Depletion Approach. Kinetics experiments
were performed as previously described (Obach and Reed-Hagen, 2002) . Briefly, compounds (1-100µM final concentration) were incubated in triplicate with CYP2D6 (0.02mg/ml) in a total volume of 1.4ml.
At times 0, 2, 5, 10, 20 and 30 min after initiation of the reactions by the addition of NADPH, 0.2ml aliquots were removed and added to 70% (v/v) perchloric acid to terminate the reaction. The mixtures were centrifuged at 12,000 x g for 5 min and the supernatant was analyzed by HPLC. MA), using a validated potentiometric method (Avdeef et al., 1993) . Briefly, stock solutions of test compounds were prepared at a concentration of 20mg/ml in dimethylsulfoxide. The pKa was determined in a mixture of water and cosolvent with a minimum of three ratios of water/cosolvent titrated to obtain an apparent pKa in the presence of cosolvent (p s K a ). The potentiometric pKa was determined by extrapolation of the p s K a values measured in the cosolvent titrations using the Yasuda-Shedlovsky technique (Avdeef et al., 1993) .
CYP2D6 Kinetics Database.
A database of small molecules with reported experimental CYP2D6 kinetics data was generated from literature sources using SciFinder Scholar (Supplemental Data Excel File). Keyword searching using the terms "CYP2D6", "substrate" and "kinetics" to identify publications that were manually inspected for relevant data. Inclusion in the database was limited to compounds that had reported Michaelis-Menten constants (K M ) obtained using purified CYP2D6 enzyme systems. The
This article has not been copyedited and formatted. The final version may differ from this version. Differences in mean property values between substrates and nonsubstrates were evaluated for statistical significance using the Student's t-test in Prism v.4.0 where, * = p < 0.05 and ** = p < 0.01.
Construction of Decision Tree Models.
The data mining software WEKA v.3.4.12 (Witten and Frank, 2005 ) was used to construct J48 decision trees that forecast CYP2D6 substrate status from an automatically selected subset of computed molecular properties. The J48 decision tree is an implementation of the C4.5 algorithm (Quinlan, 1993) . Compounds were classified as substrates if the K M value was less than or equal to 25µM, while nonsubstrates were considered to be compounds Molecular properties for compounds were computed as described above using ACD Labs software and were manually transformed from a tab-delimited file format to the required input ARFF file format (format described at http://www.cs.waikato.ac.nz/~ml/weka/arff.html). The J48/C4.5 decision tree algorithm performs an automated variable selection to identify decision trees with the most statistically meaningful descriptors. It is important to note however that statistical significance does not necessarily imply scientific significance, thus thorough inspection and interpretation of the resulting decision trees were necessary.
Models were initially constructed using a 10-fold cross-validation technique to assess potential overfitting. In n-fold cross-validation, the supplied data set is randomly partitioned into n groups and one partition is withheld from construction and used to test the model, while the remaining partitions are used for model construction. Model rebuilding is performed n times with a new partition withheld each cycle to allow all the compounds in the input set to be used at least once in testing.
In order to assess the potential impact of different chemical scaffolds on resulting model structure, we created three different models described in the Supplementary Information file. Each model was built on a differently randomized subset of compounds in the CYP2D6 substrate database. To identify a construction or training set of compounds and a validation or testing set, all database members were randomly assigned a number from 0 to 1. Compounds with a random number greater than or equal to 0.7 were assigned to the test set, while the other compounds were retained in the training set.
Compounds in the test set were not used in model construction. This process was repeated a total of three different times to generate three different training and test sets.
Model performance was primarily evaluated using classification accuracy, sensitivity and specificity as defined below in Equations 1 -3. TP (true positive) and TN (true negative) refer to compounds that are correctly assigned as a substrate or nonsubstrate, respectively. Likewise, FP (false 
Synthesis. Minozac, MW01-5-079HAB, and MW01-5-042HAB were synthesized and characterized as previously described (Hu et al., 2007) . Synthetic reaction progress was monitored by HPLC and final products were characterized by mass spectrometry, HPLC and 1 H NMR as previously described (Hu et al., 2007) . Yields of final compounds were determined gravimetrically.
General Procedure for the Synthesis of Aminated Pyridazines. Two general methods (A and B) were
used for the synthesis of aminated pyridazines. Method A. A mixture of the appropriate chloropyridazine precursor (1 equiv) and amine in solvent were reacted by microwave irradiation (CEM Discover, Matthews NC) in a capped 10ml microwave glass vessel. Microwave irradiation of 125W was used, ramping from ambient temperature to 175 ºC. Upon reaching the set temperature of 175 ºC, the reaction mixture was held for 3 hours, allowed to cool to ambient temperature and purified to obtain product.
Method B. The appropriate chloropyridazine precursor (1 equiv) and amine were refluxed in 1-butanol under argon gas. The solvent was removed under reduced pressure and further purified to afford the final product.
MW01-1-085HAB; N-(2-morpholinoethyl)-6-phenylpyridazin-3-amine. 2-Morpholinoethanamine
(1.3 g, 10.5 mmol) and 3-chloro-6-phenyl-pyridazine (500 mg, 2.62 mmol) were reacted according to 
MW01-7-121HAB; 4-methyl-6-phenyl-N-(2-(tetrahydro-2H-pyran-4-yl)ethyl)pyridazin-3-amine.
2-(Tetrahydro-pyran-4-yl)ethylamine (813 mg, 5.86 mmol) and 3-chloro-4-methyl-6-phenylpyridazine (300 mg, 1.47 mmol) were reacted in water according to Method A. The product was purified by solid phase extraction using equilibrated Waters Sep-Pak® C18 cartridges (Milford, MA), and eluted with 5% 
MW01-7-103HAB; 4-methyl-6-phenyl-N-(2-(piperidin-1-yl)ethyl)pyridazin-3-amine. N-(2-
Aminoethyl)piperdine (1.32 ml, 9.19 mmol) and 3-chloro-4-methyl-6-phenylpyridazine (470 mg, 2.30 mmol) were reacted in water according to Method A. Upon cooling, the water was decanted from the mixture and the remaining oil was subsequently dissolved in methylene chloride, extracted with water, and dried over sodium sulfate. The solvent was evaporated under reduced pressure to produce a yellow oil that was triturated with ether to give a yellow solid collected and dried in vacuo to afford product in 
MW01
MW01-2-
3-Chloro-4-methyl-6-phenylpyridazine (1.0 g, 4.9 mmol) and N 1 ,N 2 -dimethylethane-1,2-diamine (1.3 g, 12.2 mmol) were reacted according to Method B for 72 h. Following evaporation, the brown-red residue was treated with water (30 ml) and dichloromethane (30 ml). After extraction with dichloromethane (3 x 30 ml), the organic layer was dried with sodium sulfate, solvent removed under reduced pressure and the residue purified by silica gel chromatography (methanol:dichloromethane, 1:20) to give N 1 ,N 2 -dimethyl-N 1 -(4-methyl-6-phenylpyridazin-3-yl)ethane-1,2-diamine in 72% yield.
The resulting amine (0.90 g, 3.51 mmol) was placed in a 38 ml pressure vessel followed by addition of 2-bromopyrimidine (0.52 g, 3.51 mmol), TEA (1.5 ml, 10.5 mmol) and 1-butanol (8 ml). The
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RESULTS
Molecular basis for differential CYP2D6 substrate status of minaprine, minozac
To evaluate the molecular basis and molecular properties associated with minaprine serving as a substrate and the contrasting CYP2D6 stability of minozac, analogs of the two compounds were synthesized and tested for CYP2D6 substrate status. The overall goal was to reverse the respective CYP2D6 substrate status of minaprine and minozac. Due to the similarities in lipophilicity, additional molecular properties reflecting physical characteristics such as charge and size were computed to identify how properties differences between the two compounds might relate to CYP2D6 substrate status. Table 1 .
The minaprine R 6 phenyl ring is the major site of metabolism in humans (Davi et al., 1981) , which is common to the 3-amino-4-methyl-6-phenylpyridazine scaffold of both drugs. A secondary site of metabolism is the R 4 methyl group, which is also common to the two drugs. However, substitution of the minaprine R 4 methyl group with a hydrogen atom yielded an analog (MW01-1-085HAB; Table 1) with a similar CYP2D6 K M value and computed physical properties. A third point of minaprine metabolism that represents that only structural difference between the two drugs is the R 3 position amine.
Therefore, the R 3 position amines represented the most logical focus to reverse CYP2D6 substrate status within the minaprine and minozac families ( Table 1 ).
The substrate status of the CYP2D6 substrate minaprine was reversed by the substitution of the minaprine R 3 morpholine ring with a piperazine ring, to yield an analog (MW01-8-071HAB) stable to CYP2D6. The reversal of CYP2D6 substrate status correlates with a decrease in LogD 7.4 (1.83 to -0.02) and an increase in basicity as measured by pKa (Table 1) . Other minaprine analogs (MW01-7-103HAB,
MW01-7-121HAB) with modified morpholine rings span a range of experimental pKa values (nearly 5
This article has not been copyedited and formatted. The final version may differ from this version. (Table 1) . Although it was rather straightforward to transform minaprine from a CYP2D6 substrate to a non-substrate with the synthesis and evaluation of a discrete set of analogs, the evaluation of molecular properties failed to reveal a simple correlation between CYP2D6 substrate status and molecular properties values.
In contrast to the approach with converting minaprine from a substrate to a non-substrate, the goal of the minozac analysis was to convert a nonsubstrate into a CYP2D6 substrate. The same approach of analog synthesis and evaluation of CYP2D6 substrate status was used. Conversion from nonsubstrate to a substrate with a K M value comparable to minaprine was accomplished by the synthesis of the minozac analog MW01-5-042HAB, in which the pyrimidine ring of minozac was substituted with a smaller methyl functionality (Table 1) 
Generation of a CYP2D6 substrate database and molecular properties pattern analysis
We generated a small molecule CYP2D6 substrate database from literature sources with estimated K M values obtained using purified enzyme sources, while excluding data from hepatocytes and Figure 3C ). Fourth, volume is a relevant molecular property for CYP2D6 given that compounds with similar molecular weights can occupy divergent threedimensional spaces, and a cluster of substrates appears ( Figure 2D 
Data mining of CYP2D6 substrate database for higher order molecular properties patterns
Decision trees are a commonly used data mining strategy that can identify complex patterns in multidimensional data sets to generate classification models (Kingsford and Salzberg, 2008) , and can yield models amenable to correlation with experimental end points (Kingsford and Salzberg, 2008) .
Inherent to the approach is the generation of multiple decision trees using the same dataset in order to reveal stable patterns. Therefore, multiple decision trees were built using the CYP2D6 substrate database described above and the WEKA data mining software suite (Witten and Frank, 2005; Quinlan, 1993) to evaluate patterns of molecular properties that might be associated with CYP2D6 substrates with this stage of the database. As detailed in the Supplementary Information, the decision trees were constructed from an automatically selected subset of computed molecular properties that best correlated with CYP2D6 substrate status, while minimizing intercorrelation with each other. One limitation of decision tree models can be the sensitivity to the composition of the training set. For example, if the data present in the training set were dominated by compounds with high LogP values, the resulting model will likely contain this as a major classification feature. Therefore, we used differently randomized sets of compounds from the database to build and computationally validate the decision trees to examine potential effects of different chemical scaffolds on model outcomes.
The resulting models varied slightly in terms of their overall appearance (Supplementary Information File 2). Two computed properties of CYP2D6 substrates consistently appeared in all models.
Both the number of rings (nRing) and lipophilicities were features consistent with CYP2D6 substrates in the three decision tree models shown. Interestingly, minaprine and minozac differ in their respective ring counts, but possess similar lipophilicities. Further, the ring differences between minaprine and minozac contribute to charge differences. Minaprine is a more basic compound with a pKa value nearly 3.5 units higher than minozac (Table 1 ). The data mining results demonstrate that simple correlations between singular molecular properties and CYP2D6 substrate status do not necessarily apply across diverse chemical scaffolds, but rather more complex combinations of molecular properties influence CYP2D6 substrate status. In this regard, the 3-amino-4-methyl-6-phenylpyridazine scaffold case study of properties and small molecule structure that can be downloaded, updated and used for future refinement and development of CYP2D6 computational tools.
The interconversion of the 3-amino-4-methyl-6-phenylpyridazine scaffold between substrate and non-substrate is due to a complex interplay of physical features that determine CYP2D6 substrate status. An unexpected issue was raised by this study for researchers interested in minimizing CYP2D6 involvement and developing CNS penetrant therapeutics. Specifically, molecular properties guidelines that include minimizing PSA and increasing LogP are often used to improve small molecule brain partitioning (Gleeson, 2008; Clark, 1999) . However, the pattern analysis of the CYP2D6 database showed that lower PSA values coincide with an increased likelihood of serving as a CYP2D6 substrate.
This article has not been copyedited and formatted. The final version may differ from this version. Earlier models addressing small molecule CYP2D6 metabolism (Haji-Momenian et al., 2003; Sciabola et al., 2007; Snyder et al., 2002) have not been fully integrated into early-stage drug discovery efforts due partly to limited accuracy in practical settings (Martin, 2006; Doweyko, 2008) . Two potential factors impacting accuracy and utility are the limited number of data points and data quality used in model construction. For example, earlier QSAR studies (Haji-Momenian et al., 2003; Snyder et al., 2002; de Groot et al., 1999) used 40 -50 compounds to build and validate models. Additionally, most reports do not emphasize K M values from purified enzyme sources, with one exception being the model reported by Snyder and colleagues (Snyder et al., 2002) . The CYP2D6 kinetics database presented here addresses both of these issues by expanding the number of publicly available data points to 92 compounds and imposing inclusion and exclusion criteria for database entry. This expanded collection minimizes the confounding involvement of other enzymes in the K M data.
It is important to note that one limitation with the database is the inclusion of only computed potential concern in using this particular property to forecast CYP2D6 substrates, despite previous reported correlations between pKa and CYP2D6 substrates (Upthagrove et al., 2001) . In contrast, other computed properties were congruent with experimental values. Future expansion of the database must consider the quality and inclusion criteria for new data entries. As shown in the construction of the decision trees, the individual properties comprising the tree varied as a result of changes to the set of compounds used in construction. If the database becomes overpopulated with certain chemical families, the resulting patterns might deviate towards the properties most relevant to the high-abundance scaffolds.
Notwithstanding, the database of disclosed CYP2D6 substrates and the reported statistical analyses of CYP2D6 substrates provide a useful tool for the future development of new computational models as well as a resource for individual drug discovery research campaigns with inclusion of future public disclosed data as well as internal proprietary data.
This article has not been copyedited and formatted. The final version may differ from this version. Statistical significance of mean differences evaluated using Student's t-test. * = p < 0.05, ** = p < 0.01.
